ON February 3, 2022 Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), reported that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences (Press release, Merus, FEB 3, 2022, View Source [SID1234607705]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim Healthcare Talks/2022 Oncology Conference (fireside chat): Thursday, February 10 at 10:30-10:55 a.m. ET
Citi’s 2022 Virtual Immuno-Oncology Summit (fireside chat including Andrew Joe, M.D., Merus Chief Medical Officer): February 16 at 1:30-2:30 p.m. ET
11th Annual SVB Leerink Global Healthcare Conference (presentation): Thursday, February 17 at 12:00-12:30 p.m. ET
The webcasts of the presentations will be contemporaneously available on the Investors page of the Company’s website. Archived presentations will also be available there for a limited time after the event.